<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39464908</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2249-4863</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of family medicine and primary care</Title><ISOAbbreviation>J Family Med Prim Care</ISOAbbreviation></Journal><ArticleTitle>Evaluation of cardiac biomarkers among dead and alive COVID-19 patients in Southwest Iran.</ArticleTitle><Pagination><StartPage>3931</StartPage><EndPage>3937</EndPage><MedlinePgn>3931-3937</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/jfmpc.jfmpc_1964_23</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The need to understand the global burden of heart failure following the pandemic has arisen as a result of an increase in papers that support cardiac involvement in coronavirus disease 2019 (COVID-19). Therefore, the current study aims to provide a more thorough explanation of the function and use of cardiac biomarkers in dead and alive COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All patients who were referred and admitted to Razi Hospital, Ahvaz, Iran, from March 2020 to March 2021 with a diagnosis of COVID-19 were included in this study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During the study period, 753 patients were hospitalized with a diagnosis of COVID-19. In total, 157 cases died from the disease (case fatality rate: 20.84%). Pre-existing cerebrovascular accidents (CVAs) were more frequent in dead cases (14% vs. 6.4%). It was observed that atrial fibrillation was normal in most of the alive cases in comparison to dead patients (<i>P</i> value = 0.014). Moreover, it was seen that CRP, IL-6, and procalcitonin were increased in dead patients. Also, an association was found between ejection fraction (EF) value and death rate (<i>P</i> value = 0.035). The higher frequency of positive troponin occurring in the dead group suggested a possible adverse effect on the mortality rate (22.3% vs. 16.4%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Adults with COVID-19 commonly have cardiac manifestations, including symptoms of myocardial damage. In light of the recognized utility of troponin, ejection fraction, procalcitonin, IL-6, and CRP in COVID-19 patients with suspected myocardial damage, we should develop a safe and precise diagnostic algorithm that may contain patients' clinical histories and additional variables that may facilitate the prediction of myopericarditis.</AbstractText><CopyrightInformation>Copyright: © 2024 Journal of Family Medicine and Primary Care.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adel</LastName><ForeName>Seyed Mohammad Hassan</ForeName><Initials>SMH</Initials><AffiliationInfo><Affiliation>Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sardabi</LastName><ForeName>Ebrahim Heydari</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiash</LastName><ForeName>Nehzat</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayadian</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pour</LastName><ForeName>Sanaz Saki</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amini</LastName><ForeName>Payam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Family Med Prim Care</MedlineTA><NlmUniqueID>101610082</NlmUniqueID><ISSNLinking>2249-4863</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ejection fraction</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39464908</ArticleId><ArticleId IdType="pmc">PMC11504751</ArticleId><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1964_23</ArticleId><ArticleId IdType="pii">JFMPC-13-3931</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57:365–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">32645276</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust. 2020;213:134–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404664</ArticleId><ArticleId IdType="pubmed">32677734</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicol M, Cacoub L, Baudet M, Nahmani Y, Cacoub P, Cohen-Solal A, et al. Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. ESC Heart Fail. 2020;7:4371–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755006</ArticleId><ArticleId IdType="pubmed">33107217</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavone M, Gobbi C, Biondi-Zoccai G, D’Ascenzo F, Palazzuoli A, Gasperetti A, et al. Acute coronary syndromes and Covid-19: Exploring the uncertainties. J Clin Med. 2020;9:1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356537</ArticleId><ArticleId IdType="pubmed">32498230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22:957–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273093</ArticleId><ArticleId IdType="pubmed">32412156</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard I, Robinson B, Dawson A, Aya A, Ali R. An atypical presentation of fulminant myocarditis secondary to COVID-19 infection. Cureus. 2020;12:e9179. doi: 10.7759/cureus.9179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425826</ArticleId><ArticleId IdType="pubmed">32802614</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Chen M, Zhang Y. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. Mol Biol Rep. 2021;48:1763–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7822398</ArticleId><ArticleId IdType="pubmed">33483864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalia T, Lahan S, Ranka S, Acharya P, Gautam A, Goyal A, et al. Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis. Indian Heart J. 2021;73:91–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719198</ArticleId><ArticleId IdType="pubmed">33714416</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5:1281–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385672</ArticleId><ArticleId IdType="pubmed">32730555</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal P, Reshetnyak E, Khan S, Musse M, Navi BB, Kim J, et al. Clinical characteristics and outcomes of adults with a history of heart failure hospitalized for COVID-19. Circ Heart Fail. 2021;14:e008354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8711641</ArticleId><ArticleId IdType="pubmed">34517720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, et al. Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: Clinical correlates and echocardiographic findings. Eur J Heart Fail. 2021;23:1891–902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239668</ArticleId><ArticleId IdType="pubmed">33932255</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation. 2020;142:342–353. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382541</ArticleId><ArticleId IdType="pubmed">32469253</ArticleId></ArticleIdList></Reference><Reference><Citation>Freaney PM, Shah SJ, Khan SS. COVID-19 and heart failure with preserved ejection fraction. JAMA. 2020;324:1499–500.</Citation><ArticleIdList><ArticleId IdType="pubmed">33001179</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:811–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Manocha KK, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the HA2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021;10:e018477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174190</ArticleId><ArticleId IdType="pubmed">33121304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zendehdel M, Elyasi F, Jahanfar S, Emami-Sahebi A. Effectiveness of progressive muscle relaxation technique on anxiety caused by Covid-19 in pregnant women: A randomized clinical trial. Neuropsychopharmacol Rep. 2022;42:158–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9216373</ArticleId><ArticleId IdType="pubmed">35182048</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol. 2020;5:831–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pink I, Raupach D, Fuge J, Vonberg R-P, Hoeper MM, Welte T, et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection. 2021;49:935–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140571</ArticleId><ArticleId IdType="pubmed">34021897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>